CFO Joshua Smiley On Lilly’s Next Decade Of Growth
Strategy Includes Product-Specific Deals In $1bn Range
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the worldwide biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Lilly reported positive results from a Phase II pivotal trial of donanemab, which targets a modified form of beta-amyloid called N3pG, and has a second pivotal Phase II study under way.
Starting patients on a low dose yielded lower rates of GI adverse events for the GIP/GLP-1 agonist, but it remains uncertain how differentiated tirzepatide will be against entrenched GLP-1 rivals.